Stock Events

Stock Events

Opthea Limited 

$0.03
0
+$0.01+75.51% Monday 15:40

Statistics

Day High
0.02
Day Low
0.02
52W High
3.41
52W Low
0
Volume
460
Avg. Volume
14,308
Mkt Cap
46.82M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-651,164%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
50,000Revenue
-325.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OPTEY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals, Inc. develops treatments for eye diseases, including Eylea, a direct competitor to Opthea's OPT-302 for wet AMD.
Regenxbio
RGNX
Mkt Cap454.19M
REGENXBIO Inc. works on gene therapies for retinal diseases, competing in the same therapeutic area as Opthea.
Bausch Health Companies
BHC
Mkt Cap2.09B
Bausch Health Companies Inc., through its subsidiary Bausch + Lomb, develops products for eye health, including treatments for AMD.
Novartis
NVSEF
Mkt Cap298.59B
Novartis AG, a major player in eye care, markets Lucentis for AMD, directly competing with Opthea's products.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc. acquired Allergan, which has a portfolio of eye care products, including treatments for retinal diseases.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG offers Lucentis in some markets and is involved in the development of other drugs for eye diseases.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. has investments in treatments for eye diseases, including AMD, positioning them as a competitor in the same field.
Biogen
BIIB
Mkt Cap25.38B
Biogen Inc. has shown interest in expanding its portfolio to include treatments for eye diseases, potentially competing with Opthea.
Novartis
NVS
Mkt Cap297.35B
Novartis International AG is a leading company in eye care, directly competing with Opthea in the AMD treatment market.

About

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Show more...
CEO
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Country
United States
ISIN
US68386J2087

Listings

MU
DE
UKJ2.MU
AU
AU
OPT.AU
F
DE
UKJ.F
OTC Link
US
OPTEY

0 Comments

Share your thoughts

FAQ

What is Opthea Limited stock price today?▼
The current price of OPTEY is $0.03 USD — it has increased by +75.51% in the past 24 hours. Watch Opthea Limited stock price performance more closely on the chart.
What is Opthea Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Opthea Limited stocks are traded under the ticker OPTEY.
What is Opthea Limited market cap?▼
Today Opthea Limited has the market capitalization of 46.82M
What is Opthea Limited revenue for the last year?▼
Opthea Limited revenue for the last year amounts to 50,000 USD.
What is Opthea Limited net income for the last year?▼
OPTEY net income for the last year is -325.58M USD.
In which sector is Opthea Limited located?▼
Opthea Limited operates in the Other sector.
When did Opthea Limited complete a stock split?▼
Opthea Limited has not had any recent stock splits.
Where is Opthea Limited headquartered?▼
Opthea Limited is headquartered in Melbourne, United States.